{"transactions":[{"id":719818,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:00:41.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":125000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-07-01","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001193125-26-294873","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526294873/ownership.xml","form_type":"4"}},{"id":968840,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option (right to buy)","published_at":"2025-12-15T22:50:51.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":5870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the issuer's 2014 Stock Incentive Plan."},{"field":"date","element":"transactionDate","label":"F2","text":"The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the reporting person continues to serve on the board of directors of the issuer."}],"balance_after":5870,"derivative":{"exercise_price":1.44,"expiration_date":"2035-12-11","underlying":"Common Stock","underlying_shares":5870},"source":{"system":"sec-edgar","filing":"0001193125-25-319508","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525319508/ownership.xml","form_type":"4"}},{"id":968839,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-15T22:50:51.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":5870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the issuer's 2014 Stock Incentive Plan."},{"field":"date","element":"transactionDate","label":"F2","text":"The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025."},{"field":"date","element":"transactionDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the \"2024 Reverse Stock Split\"). Upon effectiveness of the 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the \"2025 Reverse Stock Split\"). Upon effectiveness of the 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock."}],"balance_after":5916,"source":{"system":"sec-edgar","filing":"0001193125-25-319508","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525319508/ownership.xml","form_type":"4"}},{"id":1096709,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T01:00:09.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.8977,"expiration_date":"2035-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-25-093469","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025093469/ownership.xml","form_type":"4"}},{"id":1387999,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-10-11T01:53:44.000Z","date":"2024-10-08","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the issuer's 2014 Stock Incentive Plan."},{"field":"date","element":"transactionDate","label":"F2","text":"The option grant was approved by the issuer's board of directors on October 8, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options will vest 100% on the first anniversary of the grant date, so long as the reporting person continues to serve on the board of directors of  the issuer."}],"balance_after":21000,"derivative":{"exercise_price":1.29,"expiration_date":"2034-10-08","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-24-114183","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585608/000095017024114183/ownership.xml","form_type":"4"}},{"id":1461368,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-03T21:00:05.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.9541,"expiration_date":"2034-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-081604","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024081604/ownership.xml","form_type":"4"}},{"id":1697223,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, no par value","published_at":"2024-01-03T00:08:49.000Z","date":"2023-12-29","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.09,"value":10900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.08 to not more than $1.09. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include common shares that may be acquired upon the exercise of stock options outstanding as of the date of this report."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001493152-24-000154","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224000154/ownership.xml","form_type":"4"}},{"id":1808220,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2023-08-14T20:55:07.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":false,"shares":1718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the issuer's 2014 Stock Incentive Plan (the \"Plan\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested in full on July 1, 2023, the first anniversary of the service start date. Vested shares were delivered to the reporting person on the vesting date provided in the grant notice, subject to the reporting person's continuous services through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested in full on July 1, 2023, the first anniversary of the service start date. Vested shares were delivered to the reporting person on the vesting date provided in the grant notice, subject to the reporting person's continuous services through such vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1718},"source":{"system":"sec-edgar","filing":"0001104659-23-091463","document":"tm2322677-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923091463/tm2322677-3_4seq1.xml","form_type":"4"}},{"id":1808219,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-14T20:55:07.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":68568,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":70286,"source":{"system":"sec-edgar","filing":"0001104659-23-091463","document":"tm2322677-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923091463/tm2322677-3_4seq1.xml","form_type":"4"}},{"id":1808218,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-14T20:55:07.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":1718,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1718,"source":{"system":"sec-edgar","filing":"0001104659-23-091463","document":"tm2322677-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923091463/tm2322677-3_4seq1.xml","form_type":"4"}},{"id":1840347,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T21:45:57.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2033-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-23-023345","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223023345/ownership.xml","form_type":"4"}},{"id":1923460,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2023-04-06T20:26:33.000Z","date":"2023-04-06","kind":"grant","planned":false,"acquired":false,"shares":1718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the issuer's 2014 Stock Incentive Plan (the \"Plan\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the issuer's common stock."},{"field":"date","element":"transactionDate","label":"F3","text":"The RSU grant, effective April 6, 2023, was approved by the issuer's board of directors on June 30, 2022, subject to the issuer having sufficient authorized shares of common stock under the Plan on or before June 30, 2023. Following the issuer's filing of a registration statement on Form S-8 on April 6, 2023 to reflect the automatic increase in the number of shares of common stock authorized for issuance under the 2014 Plan in an amount equal to 5% of the total number of shares outstanding on December 31st of the preceding calendar year pursuant to the terms of the Plan, the Company had sufficient authorized shares of common stock under the Plan for the RSU grant and the RSU grant became effective as of such date."},{"field":"shares","element":"transactionShares","label":"F4","text":"The issuer's board of directors originally approved the grant of 128,851 RSUs on June 30, 2022, subject to the conditions described in footnote 3 above. On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the \"Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. As a result, the 128,851 RSUs originally approved by the Board were adjusted to 1,718 RSUs to reflect the Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vest in full on July 1, 2023, the first anniversary of the service start date. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice, subject to the reporting person's continuous services through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vest in full on July 1, 2023, the first anniversary of the service start date. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice, subject to the reporting person's continuous services through such vesting date."}],"balance_after":1718,"derivative":{"underlying":"Common Stock","underlying_shares":1718},"source":{"system":"sec-edgar","filing":"0001104659-23-042746","document":"tm2311973-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923042746/tm2311973-1_4seq1.xml","form_type":"4"}},{"id":2213194,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T20:15:54.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-018683","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018683/ownership.xml","form_type":"4"}},{"id":2648695,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T22:17:26.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2022, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":2.86,"expiration_date":"2031-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-21-015880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315221015880/ownership.xml","form_type":"4"}},{"id":2725618,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-06T21:48:58.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 36 monthly installments beginning on the one-month anniversary of the date of grant, subject to the reporting person's continuous service on the board of directors of the issuer."}],"balance_after":90000,"derivative":{"exercise_price":2.58,"expiration_date":"2031-05-03","underlying":"Common Shares","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001493152-21-010668","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315221010668/ownership.xml","form_type":"4"}}]}